Market News & Trends
NovelMed's Ruxoprubart Receives FDA Orphan Drug Designation for Paroxysmal Nocturnal Hemoglobinuria Treatment
NovelMed recently announced the US FDA has granted Orphan Drug Designation (ODD) to Ruxoprubart, an alternative pathway (AP) blocker anti-Bb antibody, for the treatment of…
Abzena Launches LabZient™, an Analytical Platform to Expedite the Path to IND for Antibodies
Abzena recently announced the launch of its new analytical platform, LabZient™. The standardized and automated platform streamlines the assessment and validation of large molecules, which significantly….
CDMO Alcami Expands Fill/Finish Manufacturing Capacity With New Charleston Line
Alcami Corporation recently announced the strategic expansion of its sterile fill/finish manufacturing capacity with the addition of a new sterile fill/finish line with isolator and two lyophilizers at….
Saghmos Therapeutics Announces Notice of Allowance for Second US Patent for Phase 3-Ready Cardiorenal Metabolic Modulator
Saghmos Therapeutics, Inc. recently announced a Notice of Allowance for a second US patent for its Phase 3-ready product, ST-62516 (trimetazidine), a cardiorenal metabolic modulator.…
Anima Biotech Announces Preclinical Data of Candidate in Idiopathic Pulmonary Fibrosis
Anima Biotech recently announced positive preclinical data of its lung fibrosis candidate. This drug operates through a novel mRNA biology mechanism of action, opening new…
Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in AL Amyloidosis
Immix Biopharma, Inc. recently announced the European Commission (EC) has granted orphan drug designation to NXC-201 for the treatment of….
FundaMental Pharma GmbH Announces Groundbreaking Proof-of-Concept Study Using a TwinF Interface Inhibitor for the Treatment of Amyotrophic Lateral Sclerosis
FundaMental Pharma GmbH recently announced the publication of a groundbreaking study by Neurobiologists in Heidelberg using FundaMental Pharma’s small molecule TwinF interface inhibitor, FP802…..
Triumvira Immunologics Announces First Patient Dosed in Phase 1/2 Cell Therapy Trial
Triumvira Immunologics recently announced the first patient has been dosed in its TACTIC-3 trial, a Phase 1/2 study (NCT05862324) investigating the safety and efficacy of…
Purolite & Repligen Announce Commercial Launch of Novel CH1 Affinity Resin for the Purification of Specialized mAbs
Purolite and Repligen Corporation recently announced the commercial launch of Praesto CH1, a new 70μm (micron) agarose-based affinity resin designed to purify specialized mAbs, such…
MiNK Therapeutics' AgenT-797 Shows Promising Results in the Treatment of Severe Acute Respiratory Distress
MiNK Therapeutics, Inc. recently announced the publication of results in Nature Communications from a Phase 1/2 study of agenT-797 in patients with moderate-to-severe acute respiratory…
Dyadic Announces Research & Development Collaboration Agreement With Global Biopharmaceutical Company
Dyadic International, Inc. recently announced it has signed a fully funded evaluation agreement including commercial option with an undisclosed leading global biopharmaceutical company to design…
Merck Animal Health to Acquire Elanco’s Aqua Business
Bolsters Merck Animal Health’s position in the aqua industry with comprehensive approach to ensure fish health, welfare and sustainability in aquaculture, conservation and fisheries….
Novo Holdings to Acquire Catalent
Catalent, Inc., a leader in enabling the development and supply of better treatments for patients worldwide, and Novo Holdings, a holding and investment company that is responsible for managing the assets and wealth of the Novo Nordisk Foundation, recently announced they….
BioXcel Therapeutics Announces USPTO’s Allowance of Patent Application for Method of Treating Agitation in Alzheimer’s Disease Using Oromucosal Formulations of Dexmedetomidine
BioXcel Therapeutics, Inc. recently announced the United States Patent and Trademark Office (USPTO) has allowed US Patent Application No. 17/496,470 with claims pertaining to a…
Curia Receives 2024 CDMO Leadership Award
Curia, a leading contract research, development and manufacturing organization, recently announced it has been awarded a 2024 CDMO Leadership Award in the Service category, Small…
Vaxart Announces Publication in Vaccines of Non-Human Primate Preclinical Data Demonstrating its Next-Generation Vaccine Candidates Elicit Mucosal & Systemic Immunogenicity & Reduce Viral Shedding After SARS-CoV-2 Challenge
Vaxart, Inc. recently announced the publication of preclinical non-human primate data demonstrating the potential of its COVID-19 vaccine to protect against multiple SARS-CoV-2 variants of…
Studies Validate Advantages of Administering Drugs to Pets Via IntelGenx’s VetaFilm Platform
IntelGenx Corp. recently announced positive results from a proof-of-concept (POC) study to assess the palatability, owner-perceived acceptability, and ease of repeated administration of IntelGenx’s VetaFilm…
Biovian & 3P Biopharmaceuticals Join Forces to Create 3PBIOVIAN
Biovian and 3P Biopharmaceuticals, two leading biologics Contract Development and Manufacturing Organizations (CDMOs), recently announced their combination to establish a new pan-European leader in their….
Purple Biotech Reaches Recommended Phase 2 Dose for NT219
Purple Biotech Ltd. recently announced it has determined 100mg/kg is the recommended Phase 2 dose (RP2D) for NT219 in combination with cetuximab in the treatment…
Denali Therapeutics Announces Presentations on its Investigational Blood-Brain Barrier-Crossing Enzyme Replacement Therapies
Denali Therapeutics Inc. recently announced upcoming presentations from its Enzyme Transport Vehicle (ETV) development programs, tividenofusp alfa (DNL310) and DNL126 (ETV:SGSH), to be given at…
